{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:41:01Z","timestamp":1760532061213,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejps.2021.105942","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T12:10:23Z","timestamp":1626264623000},"page":"105942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Population exposure-response model of 131I in patients with benign thyroid disease"],"prefix":"10.1016","volume":"165","author":[{"given":"Valentina","family":"Topi\u0107 Vu\u010denovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvezdana","family":"Rajkova\u010da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijana","family":"Jeli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragi","family":"Stanimirovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10047","key":"10.1016\/j.ejps.2021.105942_bib0001","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"De Leo","year":"2016","journal-title":"Hyperthyroidism. The Lancet"},{"issue":"10","key":"10.1016\/j.ejps.2021.105942_bib0002","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ejps.2021.105942_bib0003","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1007\/s00259-010-1536-8","article-title":"EANM procedure guidelines for therapy of benign thyroid disease","volume":"37","author":"Stokkel","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ejps.2021.105942_bib0004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00259-016-3548-5","article-title":"Radioiodine - the success story of nuclear medicine: 75th anniversary of the first use of iodine-131 in humans","volume":"44","author":"McCready","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a european survey","volume":"4","author":"Sjogreen Gleisner","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40336-015-0148-5","article-title":"Dose optimization in nuclear medicine therapy of benign and malignant thyroid diseases","volume":"4","author":"H\u00e4nscheid","year":"2015","journal-title":"Clin Transl Imaging"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146645319838665","article-title":"ICRP Publication 140: radiological protection in therapy with radiopharmaceuticals","author":"Yonekura","year":"2019","journal-title":"Ann ICRP 48"},{"issue":"10","key":"10.1016\/j.ejps.2021.105942_bib0008","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2967\/jnumed.117.206649","article-title":"The relevance of dosimetry in precision medicine","volume":"59","author":"Lassmann","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ejps.2021.105942_bib0009","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s00259-013-2387-x","article-title":"EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry II. dosimetry prior to radioiodine therapy of benign thyroid diseases","volume":"40","author":"Hanscheid","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ejps.2021.105942_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5937\/arhfarm1706333T","article-title":"Challenges and current views on dosing of radioactive iodine in the treatment of benign thyroid disease","volume":"67","author":"Topi\u0107 Vu\u010denovi\u0107","year":"2017","journal-title":"Arh Farm"},{"key":"10.1016\/j.ejps.2021.105942_bib0011","first-page":"11","article-title":"2013\/59\/Euratom laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89\/618\/Euratom, 90\/641\/Euratom, 96\/29\/Euratom, 97\/43\/Euratom and 2003\/122\/Euratom","volume":"L13","year":"2014","journal-title":"Off.l J. European Union"},{"issue":"11","key":"10.1016\/j.ejps.2021.105942_bib0012","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1210\/jc.2014-1347","article-title":"Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not","volume":"99","author":"Krohn","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ejps.2021.105942_bib0013","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1088\/0031-9155\/41\/10\/001","article-title":"Dose-rate effects in targeted radiotherapy","volume":"41","author":"Dale","year":"1996","journal-title":"Phys. Med. Biol"},{"issue":"2","key":"10.1016\/j.ejps.2021.105942_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1667\/RR14766.1","article-title":"Cellular response to exponentially increasing and decreasing dose rates: implications for treatment planning in targeted radionuclide therapy","volume":"188","author":"Solanki","year":"2017","journal-title":"Radiat Res"},{"issue":"3","key":"10.1016\/j.ejps.2021.105942_bib0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1118\/1.2836421","article-title":"Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry","volume":"35","author":"Baechler","year":"2008","journal-title":"Med Phys"},{"key":"10.1016\/j.ejps.2021.105942_bib0016","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-3-319-26236-9_6","article-title":"Radiobiology and radiation dosimetry in nuclear medicine","author":"Salvatori","year":"2017","journal-title":"Nuclear Oncology"},{"key":"10.1016\/j.ejps.2021.105942_bib0017","article-title":"Investigation of factors influencing radioiodine ((131)I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach","author":"Topic Vucenovic","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0018","first-page":"47","article-title":"The radiobiology of conventional radiotherapy and its application to radionuclide therapy","volume":"20","author":"Dale","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0019","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: usage, interpretation and challenges","volume":"64","author":"McMahon","year":"2018","journal-title":"Phys. Med. Biol."},{"issue":"3","key":"10.1016\/j.ejps.2021.105942_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2021.105942_bib0021","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.ejps.2021.105942_bib0022","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.ejps.2021.105942_bib0023","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1118\/1.2964089","article-title":"A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism","volume":"35","author":"Strigari","year":"2008","journal-title":"Med Phys"},{"issue":"1\u20134","key":"10.1016\/j.ejps.2021.105942_bib0024","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/rpd\/ncv061","article-title":"Patient dosimetry in nuclear medicine","volume":"165","author":"Mattsson","year":"2015","journal-title":"Radiat Prot Dosimetry"},{"year":"1989","series-title":"NONMEM 7.4 Users Guides","author":"Beal","key":"10.1016\/j.ejps.2021.105942_bib0025"},{"key":"10.1016\/j.ejps.2021.105942_bib0026","unstructured":"Karlsson, M.O., Nordgren, R., Freiberga, S., Ueckert, S., Yngman, G. (2020) Pearl speaks NONMEM version 4.9.0, https:\/\/uupharmacometrics.github.io\/PsN\/."},{"year":"2020","series-title":"R: A language and Environment For Statistical Computing","key":"10.1016\/j.ejps.2021.105942_bib0027"},{"year":"2020","series-title":"RStudio: Integrated Development For R","key":"10.1016\/j.ejps.2021.105942_bib0028"},{"key":"10.1016\/j.ejps.2021.105942_bib0029","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and Simulation Workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.ejps.2021.105942_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10928-008-9098-0","article-title":"Comparison of proportional and differential odds models for mixed-effects analysis of categorical data","volume":"35","author":"Kjellsson","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"10.1016\/j.ejps.2021.105942_bib0031","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40262-012-0014-9","article-title":"Pharmacodynamic Models for Discrete Data","volume":"51","author":"Paule","year":"2012","journal-title":"Clin. Pharmacokinet."},{"year":"2011","series-title":"Pharmacokinetic-Pharmacodynamic Modeling and Simulation","author":"Bonate","key":"10.1016\/j.ejps.2021.105942_bib0032"},{"key":"10.1016\/j.ejps.2021.105942_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/9780470594001.app1","article-title":"Analysis of Ordinal Categorical Data","author":"Agresti","year":"2010","journal-title":"Wiley Series Probab. Statist."},{"key":"10.1016\/j.ejps.2021.105942_bib0034","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2021.105942_bib0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijrobp.2012.03.034","article-title":"Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy","volume":"85","author":"Bakhshandeh","year":"2013","journal-title":"Int. J. Radiat. Oncol Biol. Phys."},{"issue":"3","key":"10.1016\/j.ejps.2021.105942_bib0036","doi-asserted-by":"crossref","DOI":"10.4103\/0973-1482.19597","article-title":"Analytical approach to estimate normal tissue complication probability using best fit of normal tissue tolerance doses into the NTCP equation of the linear quadratic model","volume":"1","author":"Kehwar","year":"2005","journal-title":"J Cancer Res Ther"},{"year":"2016","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson","key":"10.1016\/j.ejps.2021.105942_bib0037"},{"issue":"6","key":"10.1016\/j.ejps.2021.105942_bib0038","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2021.105942_bib0039","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3758\/BF03206482","article-title":"AIC model selection using Akaike weights","volume":"11","author":"Wagenmakers","year":"2004","journal-title":"Psychon Bull Rev"},{"issue":"1","key":"10.1016\/j.ejps.2021.105942_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1118\/1.598171","article-title":"Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy","volume":"25","author":"Howell","year":"1998","journal-title":"Med. Phys."},{"issue":"5","key":"10.1016\/j.ejps.2021.105942_bib0041","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3413\/nukmed-0151","article-title":"[Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry]","volume":"47","author":"Oehme","year":"2008","journal-title":"Nuklearmedizin"},{"issue":"3","key":"10.1016\/j.ejps.2021.105942_bib0042","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MNM.0b013e328333d303","article-title":"Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?","volume":"31","author":"Kobe","year":"2010","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.ejps.2021.105942_bib0043","doi-asserted-by":"crossref","DOI":"10.1118\/1.4788660","article-title":"Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease","volume":"40","author":"Willegaignon","year":"2013","journal-title":"Med. Phys."},{"issue":"2","key":"10.1016\/j.ejps.2021.105942_bib0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-2000-5807","article-title":"Radioiodine therapy in graves' hyperthyroidism: determination of individual optimum target dose","volume":"108","author":"Haase","year":"2000","journal-title":"Exp Clin. Endocrinol. Diabet."},{"issue":"6","key":"10.1016\/j.ejps.2021.105942_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MNM.0000000000000826","article-title":"Dosimetry-based treatment for Graves' disease","volume":"39","author":"Hyer","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"9","key":"10.1016\/j.ejps.2021.105942_bib0046","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00259-002-0877-3","article-title":"Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome","volume":"29","author":"Reinhardt","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ejps.2021.105942_bib0047","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s12020-014-0398-4","article-title":"Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm","volume":"48","author":"Schiavo","year":"2015","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.ejps.2021.105942_bib0048","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/jc.2007-0879","article-title":"Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease","volume":"92","author":"Markovic","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejps.2021.105942_bib0049","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocr Rev"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:00:03Z","timestamp":1760529603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721002451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"alternative-id":["S0928098721002451"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105942","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population exposure-response model of 131I in patients with benign thyroid disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105942"}}